Erythropoietin is a protein hormone, produced in response to anemia and anoxia, which stimulates erythropoiesis (1) and appears to play an integral role in the homeostasis of the circulating red cell mass. The factors stimulating the production of the hormone and the time relationships involved in its production have been studied extensively (1, 2) , but little is known about the kinetics of its catabolism. Knowledge about metabolism of erythropoietin is necessary for full understanding of the dynamics of controlling red blood cell production.
The catabolism of specific proteins has been studied by labeling the pure protein with radioactive isotopes and following a rate of decline in serum or total body radioactivity (3) . This technique requires that the protein being labeled be both completely pure and undamaged. Erythropoietin has not been purified; hence this technique cannot be used to study its metabolism.
If, however, the endogeneous production of a substance is stopped or markedly reduced, the characteristics of disappearance of the material from the serum may be followed to estimate the rate of catabolism. Transfusion is known to suppress the production of erythropoietin (4) . Therefore, we have estimated the rate of catabolism of erythropoietin in patients with anemia, depressed erythropoiesis, and high serum erythropoietin titer by administering transfusions sufficient to raise the hemoglobin above 11 g per 100 ml. The rate of disappearance of the hormone from the blood or urine was then determined. To estimate the contribution of urinary excretion to the metabolism of erythropoietin, we have * Submitted for publication April 9, 1963; accepted February 24, 1964 .
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Materials and Methods
Nine studies were done in 8 patients, all of whom had deficient erythropoiesis due to various causes (see Table I ). At the onset of each study, the hemoglobin concentration was between 6.0 and 8.0 g per 100 ml. Packed red blood cells from 1,500 to 2,000 ml of blood were infused within 4 hours. At the termination of these initial transfusions and at appropriate intervals for several days thereafter, 20 to 25 ml of blood was drawn under sterile conditions, the clot was allowed to retract, and the serum was removed and frozen until assayed for erythropoietin. Urine was collected in 8-or 24-hour samples for the period of the study and immediately frozen. During the period of study frequent determinations of hemoglobin concentration in whole blood were performed. The level of hemoglobin was maintained above 10.0 g per 100 ml by further transfusions as necessary.
The samples of serum and urine were assayed by a previously published technique using transfused polycythemic mice (5) . Female NIH strain mice weighing 18 to 22 g were given an intraperitoneal injection of an 80% suspension of homologous red blood cells on days 1 and 2 (0.7 ml each) and day 5 (0.4 ml) of the assay. On days 5 and 6, 0.5 ml of serum or urine to he tested was injected subcutaneously, with 8 animals used to assay each material. On day 7, 0.5 jac of Fe's citrate in 0.1 ml 0.15 M NaCl was injected intraperitoneally. On day 9, the mice were bled by decapitation into tared bottles, which were reweighed, and the radioactivity due to Fe'9 was determined using a well-type scintillation counter. (6) . With this assay, 0.03 U of erythropoietin gave a response significantly different from the saline controls. The dose response curve is linear between 0.12 and 2.4 U per ml. Samples with a titer above this maximal level were diluted with appropriate amounts of saline and reassayed. All samples in a given study were diluted by the same amount. The rate of disappearance of serum erythropoietin was calculated by expressing the amount of erythropoietin present at a given time as percentage -of the amount present at the conclusion of the initial transfusions. This value was plotted on the logarithmic ordinate of semilogarithmic paper against time in hours after the conclusion of the initial transfusions ( Figure 1 ).
The line derived by the least squares method, with x as time in hours and y as the natural logarithm of the percentage of remaining activity, was calculated for these points. The renal clearance of erythropoietin was determined in 6 patients in addition to the studies on patient J.C. Urine was collected for known periods of time (2 to 8 hours) and immediately frozen. Blood was drawn for serum samples at the mid-point of the collection period.
All urine was assayed without further treatment.
Results
Nine studies in 8 patients are summarized in Table II . The erythropoietin titer at the onset of studies ranged from 4.3 to 0.43 U per ml (average, 1.4 U per ml). In six of these studies, J.C. (second study), J.F., E.F., A.H., R.C., and J.O. (Figure 1 ), the level of serum erythropoietin at the conclusion was less than 7%o of that at the onset, and in all six instances approached the minimal detectable concentration. In all cases, the declining portion of the graph of erythropoietin level against time could be approximated by a single exponential function. In three studies in 2 patients, this period of exponential decline was preceded by a lag phase of 10 to 18 hours during which the level of erythropoietin remained relatively constant. The coefficient of correlation of the calculated least squares line of all studies ranged from 0.840 to 0.993 and averaged 0.957. The mean value of half-times of serum erythropoietin disappearance for all studies was 24.9 hours (range, 6.6 to 42.6).
In patient J.C., the rate of decline of urinary erythropoietin activity after transfusion was estimated. In Figure 2 , the units of erythropoietin excreted in the urine per hour are plotted on semilogarithmic paper against the time after transfusion. The decline of erythropoietin level in the urine had the same characteristics as that in the serum. The renal clearance of erythropoietin was found in this and 6 other patients to range between 0.06 ml per minute and 0.67 ml per minute (Table III). Discussion
The mean half-time of disappearance of serum erythropoietin in patients with erythroid hypoplasia in these studies wvas 24.9 hours, with a range between 6.6 and 42.6 hours. The reduction of erythropoietin titer in the serum after transfusion is the result of two processes: 1) the cessation of production and release into the serum and 2) the catabolism and loss of erythropoietin. Production of the hormone was clearly reduced to insignificant levels at some point during the course of the study in at least 6 cases, since less than 7%o of the initial titer was present at the TJ,r/8. conclusion of the studies. If the production of the hormone were reduced to insignificant levels by, or shortly after, the completion of the transfusions, the decline in serum would reflect the rate of catabolism of the hormone. If both hormone production and noninstantaneous catabolism were taking place during the period of decline in serum level, a complex curve that could not be approximated by a single exponential function would result, except in the unlikely event that the decline in synthesis and the catabolism of the hormone were both exponential functions with the same rate constant. In the present stud- production during the period immediately after the transfusions, but this does not invalidate the assumption of insignificant production during the period of exponential decline, the only period used to measure the survival t4. On the other hand, it is theoretically possible that erythropoietin was almost instantaneously catabolized and that the decline seen in serum level was due to the gradual cessation of production. The studies of Stohlman and Brecher clearly show, however, that the catabolism of erythropoietin is not instantaneous in rats. In their studies, erythropoietin was injected into normal rats, and the rate of decline of the serum level was measured by bioassay (7) . After a distribution phase, the serum level declined with a tj of 3 to 5 hours. This tj corresponded well with the decline of serum level of erythropoietin of rats brought from simulated altitude to normal oxygen tensions (8) . This suggests that catabolism without significant persistent production is the major factor responsible for the decline in serum erythropoietin after the removal of the stimulus for erythropoietin production.
Although an order of magnitude for the survival tA of erythropoietin in the serum of patients with diminished erythropoiesis emerged, there was a considerable range in the values for different patients. The factors controlling the catabolism or loss of erythropoietin, as well as the sites of these processes, are not well defined. Loss of erythropoietin into the urine clearly represents one factor in the over-all metabolism of erythropoietin. The presence of erythropoietin in the urine has been previously well documented, and in fact urine from anemic patients and' animals has been used as a source of the hormone (9) (10) (11) (12) . Since the kidney is the major site of production of erythropoietin (13) , urinary erythropoietin may represent direct excretion into the urine by the producing cells or clearance of the serum or both.
In the studies in patient J.C., the urinary excretion was roughly proportional to the serum level throughout the study time, suggesting that the urinary erythropoietin was derived from the serum, since, as discussed albove, production had probably been suppressed by the transfusion early in the study. The renal clearance rates as calculated from these present studies (Table III) ( 14) . Erythropoietically active bone marrow is said to decrease the survival time of the hormone in rats (8) and man (15) . In the present study there was no apparent correlation between the tj of erythropoietin survival and the renal or hepatic function of the patient, as evaluated by standard clinical tests, or the erythropoietin level at the onset of the studies or the hemoglobin levels obtained during the study. It is difficult to be certain that the degree of erythroid hypoplasia was the same in all patients. Patient D.H., with the shortest erythropoietin survival, had the highest reticulocyte count. The remaining patients, however, all had apparently comparable severe erythroid hypoplasia of the marrow, reticulocytopenia, and deficient incorporation of Fe59 or glycine-2-Cl4 into erythrocytes. Since these patients with marked erythroid hypoplasia had a fairly rapid rate of hormone degradation, organs other than the erythropoietic bone marrow must play an important role in the degradation of erythropoietin.
The knowledge that erythropoietin has an appreciable survival time may help in understanding certain observations about the kinetics of erythropoiesis. In animal experiments Erslev noted persistence of reticulocytosis for several days after a brief period of anemia (16) . If colchicine was administered before the period of anemia, the onset of reticulocytosis was delayed for 2 days but was of equivalent degree. The persistence of
